Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL17603742 | 0.97 | SLC6A3 (0.39) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 | |
| SCHEMBL17117210 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL17603824 | 0.79 | HTR3A (0.41) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 | |
| SCHEMBL170771 | 0.74 | HTR3A (0.50) | SLC6A3SLC6A2SLC6A4HTR3A | |
| SCHEMBL14458006 | 0.74 | TP53 (0.51) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 | |
| SCHEMBL22201142 | 0.74 | TP53 (0.51) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 | |
| SCHEMBL1499046 | 0.73 | TP53 (0.41) | SLC6A3SLC6A2SLC6A4ALDH1A1TP53 | |
| SCHEMBL21009133 | 0.71 | TP53 (0.46) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 | |
| SCHEMBL4624667 | 0.71 | SLC6A3 (0.45) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 | |
| SCHEMBL8442229 | 0.71 | SLC6A3 (0.43) | SLC6A3SLC6A2SLC6A4HTR3AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083400-A1 | TRICYCLIC GUANIDINE DERIVATIVE | PDE3A, PDE2A, PDE5A | SLC6A3 2505/4885SLC6A2 3176/4885SLC6A4 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.